| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 22, 2015 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,303 | -- | 45,068 | |
| Jul 22, 2015 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,758 | -- | 14,758 | |
| Jul 22, 2015 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,737 | -- | 5,737 | |
| Jul 16, 2015 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | $15.27 | 29,659 | |
| Jul 16, 2015 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | -- | -- | |
| Jun 08, 2015 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,649 | $16.55 | 26,308 | |
| Jun 08, 2015 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,649 | -- | -- | |
| Apr 24, 2015 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 40,765 | |
| Feb 13, 2015 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,100 | $15.27 | 46,801 | |
| Feb 13, 2015 | SVP, GM - Oncology | Form 4 | Open market or private sale of non-derivative or derivative security | 18,100 | $18.53 | 28,701 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.